Analyst Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at $79.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alec Stranahan has given his Buy rating due to a combination of factors including the promising potential of Crispr Therapeutics AG’s in vivo gene editing approach. The company’s updated timeline for the CTX320 asset, targeting Lp(a), aligns well with the expected outcomes from the HORIZON trial, providing a clearer picture of the impact on functional outcomes. This alignment offers a significant opportunity for value creation if the results are positive.
Additionally, the updated data for CTX310, targeting ANGPTL3, shows competitive reductions in triglycerides and LDL, with a strong safety profile, reinforcing confidence in the company’s approach. The continued interest in gene editing, as evidenced by recent industry acquisitions, highlights the potential for further business development opportunities for Crispr Therapeutics AG. The company’s diverse and robust pipeline, along with its strategic positioning, supports the Buy rating with a price objective of $79.
In another report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $82.00 price target.